SCHEMBL5111065

SCHEMBL5111065

NC(=O)c1ccc(-c2ccc3nc(NCc4ccc(S(N)(=O)=O)cc4)nc(NC4CC4)c3n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.44
VCP P55072 1/20 0.42
AXL P30530 1/20 0.42
TYRO3 Q06418 1/20 0.42
MERTK Q12866 1/20 0.42
CA1 P00915 11/20 0.40
CA2 P00918 11/20 0.40
CA9 Q16790 11/20 0.40
CA12 O43570 5/20 0.40
CA14 Q9ULX7 5/20 0.40
CSNK2A1 P68400 2/20 0.40
PTGS2 P35354 1/20 0.40
DYRK1A Q13627 1/20 0.40
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA13 Q8N1Q1 1/20 0.39
CA5B Q9Y2D0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5112869 0.91 AXL (0.45) SYKVCPAXLTYRO3MERTK
SCHEMBL5111068 0.89 CA1 (0.46) SYKVCPAXLTYRO3MERTK
SCHEMBL5107326 0.88 PTGS2 (0.43) SYKAXLTYRO3MERTKCA1
SCHEMBL5115266 0.86 VCP (0.44) VCPCA1CA2CA9CA12
SCHEMBL14131409 0.85 SYK (0.40) SYKVCPAXLTYRO3MERTK
SCHEMBL5121961 0.84 PTGS2 (0.46) CA1CA2CA9CA12CA14
SCHEMBL14131703 0.84 SYK (0.39) SYKVCPAXLTYRO3MERTK
SCHEMBL5123251 0.84 SYK (0.39) SYKVCPAXLTYRO3MERTK
SCHEMBL5122098 0.83 CA1 (0.42) VCPCA1CA2CA9CA12
SCHEMBL5116817 0.81 PTGS2 (0.42) VCPAXLTYRO3MERTKCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PNP SYK 3435/4885VCP 4525/4885AXL 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.